New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
16:09 EDTAMRIAMRI closes Cedarburg deal, sees adding 6c-7c to FY14 adjusted EPS
AMRI announced that it has completed the previously announced acquisition of Cedarburg Pharmaceuticals. Total consideration paid was $41M, including assumption of certain liabilities. AMRI financed the transaction with cash on hand. The acquisition is expected to add between $13M-$14M to AMRI's revenue in FY14. AMRI anticipates full year run-rate synergies of approximately $1.5M of EBITDA within 12 months of closing and the acquisition is expected to be accretive to AMRI's FY14 adjusted diluted EPS in the range of 6c-7c per share.
News For AMRI From The Last 14 Days
Check below for free stories on AMRI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for AMRI

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use